ChemoCentryx, Inc. Appoints Anne-Marie S. Duliege, M.D., M.S. To Chief Strategic Development Role And Head Of Immuno-Oncology

MOUNTAIN VIEW, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today that it has appointed Anne-Marie S. Duliege, M.D., M.S., to a newly created position within the Company. Effective immediately, Dr. Duliege will be acting as Executive Vice President, Chief of Strategic Development and Head of Immuno-oncology.

Help employers find you! Check out all the jobs and post your resume.